Last Updated: November 16, 2026

Investigational Drug Information for Tropifexor

« Back to Dashboard


What is the drug development status for Tropifexor?

Tropifexor is an investigational drug.

There have been 7 clinical trials for Tropifexor. The most recent clinical trial was a Phase 2 trial, which was initiated on September 9th 2015.

The most common disease conditions in clinical trials are Fatty Liver, Non-alcoholic Fatty Liver Disease, and Liver Cirrhosis. The leading clinical trial sponsors are Novartis Pharmaceuticals, Allergan, and [disabled in preview].

Recent Clinical Trials for Tropifexor
TitleSponsorPhase
Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH)Novartis PharmaceuticalsPhase 2
The Purpose of This Study is to Investigate Safety and Tolerability of Tropifexor.Novartis PharmaceuticalsPhase 1
Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.Novartis PharmaceuticalsPhase 2

See all Tropifexor clinical trials

Clinical Trial Summary for Tropifexor

Top disease conditions for Tropifexor
Top clinical trial sponsors for Tropifexor

See all Tropifexor clinical trials

Tropifexor Development Update and Market Projection

Last updated: September 8, 2026

Tropifexor, also known as LJN452, is an oral, non-bile-acid farnesoid X receptor agonist developed by Novartis for metabolic dysfunction-associated steatohepatitis, formerly called nonalcoholic steatohepatitis, and cholestatic liver diseases. Public development activity has not produced an approval, commercial launch, or validated late-stage registration path. The base-case commercial projection is therefore zero near-term revenue. A meaningful value recovery would require Novartis or another sponsor to restart clinical development and establish a differentiated safety profile against resmetirom and emerging MASH therapies.

What is the current development status of tropifexor?

Tropifexor remains an investigational drug with no FDA, European Medicines Agency, or other major-market approval.

Novartis evaluated tropifexor in nonalcoholic steatohepatitis and primary biliary cholangitis. The program generated evidence of pharmacodynamic activity, including reductions in liver fat and liver enzymes, but development was constrained by class-related tolerability concerns, particularly pruritus and lipid changes.

Tropifexor development timeline

Period Development event Commercial significance
2015-2016 Early clinical studies initiated in liver disease Established FXR target engagement
2018-2019 Phase 2 NASH data reported Demonstrated reductions in liver fat and alanine aminotransferase
2019-2021 Additional studies evaluated dose, safety, and liver outcomes Pruritus and lipid effects remained relevant liabilities
2021 onward No visible transition into a pivotal registration program Reduced probability of independent commercialization
2024 No FDA approval or marketed product No product revenue or Orange Book exclusivity

Clinical studies evaluated multiple once-daily doses, including low-dose regimens intended to preserve FXR activity while limiting adverse events. Tropifexor’s clinical profile was consistent with the broader FXR class: biological activity was observable, but tolerability and long-term outcome requirements limited development economics.

What clinical evidence supports tropifexor in MASH and NASH?

The principal clinical opportunity was MASH, where FXR activation can influence bile-acid signaling, hepatic inflammation, fibrosis, and metabolic pathways.

In a Phase 2 study, tropifexor reduced liver fat measured by magnetic resonance imaging-based techniques and lowered alanine aminotransferase in selected dose groups. The study was short and was not designed to establish long-term fibrosis benefit or clinical outcomes such as decompensation, transplantation, or liver-related mortality.

Key clinical strengths

  • Oral, once-daily administration.
  • High potency at low doses.
  • Measurable liver-fat reduction.
  • Potential activity across steatohepatitis and cholestatic liver disease.
  • Mechanistic relevance to bile-acid and hepatic metabolic signaling.

Key clinical weaknesses

  • Pruritus, a recognized FXR-class adverse event.
  • Potential low-density lipoprotein cholesterol elevation.
  • Limited evidence of durable fibrosis improvement.
  • No demonstrated reduction in liver-related clinical events.
  • Competition from approved and late-stage non-FXR therapies.

The clinical bar has risen since early tropifexor studies. Resmetirom received FDA approval in March 2024 for adults with noncirrhotic MASH with moderate-to-advanced fibrosis, in conjunction with diet and exercise. This gives developers a commercial benchmark for histologic efficacy, labeling, safety management, and payer positioning (U.S. Food and Drug Administration, 2024).

What is the FDA regulatory status of tropifexor?

Tropifexor has no FDA approval, tentative approval, breakthrough designation publicly linked to a marketing application, or approved label.

There is no publicly established New Drug Application for tropifexor. The candidate therefore has no approved indication, approved dosage, approved manufacturing process, or FDA-recognized product exclusivity.

Regulatory category Tropifexor status
FDA approval None
Approved indication None
Approved dosage form None
New Drug Application approval None publicly identified
Orphan-drug approval None publicly identified
Orange Book listing None
Commercial launch None

What patents protect tropifexor?

Tropifexor is expected to have been covered by Novartis-originated composition-of-matter, pharmaceutical-composition, and therapeutic-use patent families. The public commercial position, however, is weaker than that of an approved product because no issued patent has been paired with an FDA-approved reference drug.

Likely patent categories

Patent category Relevance to tropifexor
Composition of matter Primary protection for the LJN452 chemical entity
Salt, polymorph, and solid-state claims May protect drug substance properties
Pharmaceutical composition May cover oral formulations and excipient combinations
Method of treatment May cover MASH, NASH, PBC, or other liver conditions
Combination therapy May cover use with metabolic or lipid-lowering agents
Manufacturing process May create route-specific production barriers

Because tropifexor is not approved, it has no Orange Book-listed patents under the FDA’s approved-drug framework. That distinction matters. Patent rights may exist independently, but they do not currently create an FDA-based generic launch barrier.

When does tropifexor lose exclusivity?

There is no commercially relevant loss-of-exclusivity date because tropifexor has not reached approval. Any composition-of-matter or use patents would need to be assessed by jurisdiction and patent family rather than through an Orange Book expiration date.

A generic company could not file an ordinary abbreviated new drug application referencing tropifexor unless the FDA first approved tropifexor as a reference product. A Paragraph IV challenge is therefore not a current commercial event.

What is the Orange Book status of tropifexor?

Tropifexor is not listed in the FDA Orange Book as an approved drug product. It has no reference-listed drug status, no Orange Book patent listing, and no regulatory exclusivity period that would delay an ANDA.

The absence of an Orange Book listing does not eliminate private patent risk. A future sponsor would need to conduct a freedom-to-operate review covering U.S. composition, formulation, use, process, and combination patents.

How strong is the tropifexor patent estate?

The patent estate is commercially unproven rather than clearly weak or strong.

Composition-of-matter protection, if still enforceable, would normally provide the most valuable barrier. Method-of-use patents for MASH or PBC would face greater validity and infringement risk because the relevant disease concepts, biomarkers, and treatment methods are crowded. Formulation and manufacturing patents would usually provide narrower protection and would be easier for a competitor to design around.

Patent-strength assessment

Factor Assessment
Composition protection Potentially high value if unexpired and enforceable
Formulation protection Likely narrower than composition claims
Method-of-use protection Moderate or uncertain commercial strength
Orange Book leverage None while unapproved
Generic litigation exposure Low today because no reference product exists
Re-entry litigation risk Material if development resumes
Manufacturing barriers Dependent on route-specific claims and process complexity

What formulation patents protect tropifexor?

No approved commercial formulation has been disclosed through an FDA label. Clinical development used oral formulations, but the commercial scope of any formulation patents cannot be inferred from clinical-trial dosing alone.

Potential formulation claims could cover:

  • Low-dose oral capsules or tablets.
  • Solid dispersions or improved dissolution systems.
  • Specific crystalline forms.
  • Stability-enhancing excipient systems.
  • Combination formulations with lipid-lowering or metabolic drugs.

A formulation-only patent would not necessarily prevent a competitor from developing a different oral formulation of the same active ingredient. A valid composition-of-matter patent would provide broader protection.

What patent litigation affects tropifexor?

No major publicly reported U.S. Hatch-Waxman litigation involving tropifexor has established a current generic-entry dispute. That outcome is consistent with the drug’s unapproved status.

No settlement agreement governing generic entry has been publicly associated with tropifexor. No biosimilar litigation is relevant because tropifexor is a small molecule, not a biologic.

Which companies are challenging tropifexor?

No company is currently known to be challenging tropifexor through a Paragraph IV ANDA filing. The competitive threat comes from substitute therapies rather than direct generic competition.

Competitive therapies

Product or class Company Status Competitive effect
Resmetirom Madrigal Pharmaceuticals FDA-approved for MASH with fibrosis Sets efficacy and reimbursement benchmark
Semaglutide Novo Nordisk Metabolic and obesity indications; liver-disease development Competes through weight loss and metabolic benefit
Tirzepatide Eli Lilly Obesity and diabetes indications; liver-disease development Potential broad metabolic positioning
Lanifibranor Inventiva Clinical development Direct oral MASH competition
Pemvidutide Altimmune Clinical development Weight loss and liver-disease positioning
Obeticholic acid Intercept Pharmaceuticals MASH program discontinued; approved in some jurisdictions for PBC before withdrawal actions Validated FXR mechanism but highlighted safety and regulatory risk

Obeticholic acid’s regulatory history weakened the commercial case for undifferentiated FXR agonists. Tropifexor would require a meaningful advantage in pruritus, lipid effects, fibrosis efficacy, or combination use.

What is the market projection for tropifexor?

The base-case forecast is no revenue through the near term because the candidate has no approved indication or active late-stage commercial program. A relaunch scenario would depend on a new sponsor, a redesigned clinical strategy, and evidence that tropifexor can overcome FXR-class limitations.

Scenario-based revenue projection

Scenario Development assumption Peak annual revenue potential
Base case No clinical restart or commercial development $0
Relaunch case Phase 2 restart followed by focused approval in MASH or PBC $250 million-$750 million
Upside case Strong fibrosis data, improved tolerability, global partnership $1 billion-$2 billion
Downside case Pruritus, LDL elevation, or lack of fibrosis benefit persists $0

These are analytical scenarios, not company guidance. The addressable MASH population is large, but the treated market will depend on fibrosis staging, diagnosis rates, payer restrictions, liver-biopsy or noninvasive-test requirements, and competition from metabolic therapies.

A successful tropifexor launch would likely require one of three positions:

  1. A safer FXR profile than obeticholic acid and other agonists.
  2. Combination use with an approved metabolic or antifibrotic therapy.
  3. A differentiated cholestatic-liver-disease indication where the clinical benefit-risk profile is more favorable.

Without one of those positions, tropifexor would face difficult pricing and adoption conditions against resmetirom and incretin-based therapies.

What generic launch risks exist for tropifexor?

Near-term generic launch risk is low because there is no approved reference product. The more important risk is development obsolescence: a revived tropifexor program could be commercially displaced before approval by better-established MASH therapies.

If tropifexor were approved, launch timing would depend on:

  • Remaining composition-of-matter patent life.
  • Regulatory exclusivity.
  • Orange Book listings.
  • Patent settlement terms.
  • Formulation and process patents.
  • Whether the approved indication supports a skinny-label generic strategy.

Because the candidate has no current approval, there is no reliable generic-entry date.

How does tropifexor compare with resmetirom?

Resmetirom has a substantially stronger current commercial position because it has FDA approval, a defined indication, a regulatory label, and a launch infrastructure. Tropifexor has a mechanistic advantage as a potent FXR agonist but lacks demonstrated market access and late-stage validation.

Metric Tropifexor Resmetirom
Mechanism FXR agonist Thyroid hormone receptor-beta agonist
FDA status Investigational Approved in 2024
MASH indication None Approved for noncirrhotic MASH with moderate-to-advanced fibrosis
Commercial revenue None Commercially launched
Orange Book status None Approved-product framework applies
Main safety concern Pruritus and lipid effects Drug interactions, liver and gallbladder-related warnings, thyroid effects
Development risk High Lower after approval
Market position Option value First approved therapy in its segment

What licensing deals involve tropifexor?

No major publicly disclosed third-party licensing transaction has established an active commercial partner for tropifexor. Novartis appears to have been the principal developer. The absence of a visible licensing deal reduces evidence that an external company has committed capital to late-stage development.

A future transaction would likely be structured around regional rights, a co-development agreement, or an option deal contingent on renewed proof-of-concept data.

Key Takeaways

  • Tropifexor is an investigational oral FXR agonist developed primarily by Novartis.
  • It has no FDA approval, marketed formulation, Orange Book listing, or product revenue.
  • Phase 2 studies showed liver-fat and enzyme activity but did not establish long-term fibrosis or clinical-outcome benefit.
  • Pruritus and lipid effects remain central class risks.
  • No current Paragraph IV challenge, biosimilar dispute, or generic settlement is publicly established.
  • Resmetirom materially raises the commercial and evidentiary bar for any tropifexor revival.
  • The base-case market forecast is $0; a successful relaunch could support estimated peak sales of $250 million to $750 million, with upside above $1 billion only under strong efficacy and tolerability assumptions.

FAQs

Is tropifexor approved for NASH or MASH?

No. Tropifexor has no FDA-approved indication for NASH, MASH, primary biliary cholangitis, or another disease.

Does tropifexor have an Orange Book patent expiration date?

No. Tropifexor is not an approved Orange Book product and therefore has no Orange Book patent expiration date.

Can generic companies launch tropifexor?

Not through a conventional ANDA pathway today because there is no approved tropifexor reference product. A future approval could create a later generic pathway subject to patent and exclusivity protections.

Is tropifexor a biosimilar risk?

No. Tropifexor is a small-molecule drug candidate. Biosimilar regulation applies to biologics, not to tropifexor.

Could tropifexor still become a commercial MASH drug?

Yes, but only after a substantial development restart. The program would need new clinical evidence showing durable fibrosis benefit, manageable pruritus and lipid effects, and a market position against resmetirom and incretin-based therapies.

References

  1. U.S. Food and Drug Administration. (2024). FDA approves first treatment for patients with liver scarring due to fatty liver disease. https://www.fda.gov
  2. ClinicalTrials.gov. (n.d.). Study of LJN452 in patients with non-alcoholic steatohepatitis. U.S. National Library of Medicine. https://clinicaltrials.gov
  3. ClinicalTrials.gov. (n.d.). Clinical studies of tropifexor in liver disease. U.S. National Library of Medicine. https://clinicaltrials.gov
  4. Trauner, M., Gulamhusein, A., Hameed, B., et al. (2022). Tropifexor in nonalcoholic steatohepatitis: Clinical activity and safety findings from a randomized trial. Hepatology.
  5. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.